A multicenter, open-label, single-arm study to evaluate long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508095-11-00

Acronym

EP0224

Enrollment

Registered

2024-07-19

Start date

2024-11-27

Completion date

Unknown

Last updated

2025-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Absence Epilepsy, Juvenile Absence Epilepsy

Brief summary

- Incidence of treatment-emergent adverse events (TEAEs) during the study - Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of investigational medicinal product (IMP) during the study

Detailed description

- Incidence of serious adverse events (SAEs) during the study - Incidence of IMP related TEAEs during the study

Interventions

DRUGbrivaracetam

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
- Incidence of treatment-emergent adverse events (TEAEs) during the study - Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of investigational medicinal product (IMP) during the study	—

Secondary

Measure	Time frame
- Incidence of serious adverse events (SAEs) during the study - Incidence of IMP related TEAEs during the study	—

Countries

Italy, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026